We are live on ! Find out more
BXRX

Baudax Bio, Inc. Common Stock

Delisted

BXRX was delisted on the 15th of November, 2023.

15 hedge funds and large institutions have $74.5K invested in Baudax Bio, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

25% more funds holding

Funds holding: 1215 (+3)

51% less capital invested

Capital invested by funds: $152K → $74.5K (-$77.6K)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.24%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
3
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$17.9K +$13.4K +23,400 +94%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$16.8K +$25.9K +45,363 New
VF
3
Virtu Financial
New York
$16K +$23.9K +41,888 New
XT
4
XTX Topco
Cayman Islands
$8.67K +$13.4K +23,426 New
State Street
5
State Street
Massachusetts
$4.29K
TRCT
6
Tower Research Capital (TRC)
New York
$4.01K +$158 +276 +3%
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$3.96K +$6.11K +10,699 New
UBS Group
8
UBS Group
Switzerland
$2.53K -$1.6K -2,812 -29%
BlackRock
9
BlackRock
New York
$295
Wells Fargo
10
Wells Fargo
California
$20 +$5 +9 +20%
Osaic Holdings
11
Osaic Holdings
Arizona
$6
Group One Trading
12
Group One Trading
Illinois
$1
Creative Planning
13
Creative Planning
Kansas
-$52.7K -45,001 Closed
Jane Street
14
Jane Street
New York
-$32K -27,342 Closed
AWM
15
Avior Wealth Management
Nebraska
+$1 +1 New

BXRX Hedge Fund Activity: Q3 2023 in Review

15 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q3 2023, worth a combined $74.5K — down 51% from $152K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BXRX positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $25.9K. The largest seller was Creative Planning, exiting entirely with an estimated $52.7K sold.

  • 15 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q3 2023, up from 12 in Q2 2023.
  • Funds reported $74.5K of Baudax Bio, Inc. Common Stock stock for Q3 2023, down 51% quarter-over-quarter.
  • 5 funds opened new Baudax Bio, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of +3 holders.
  • The largest Baudax Bio, Inc. Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $25.9K added.
  • The largest Baudax Bio, Inc. Common Stock seller in Q3 2023 was Creative Planning, an estimated $52.7K sold.

Based on aggregated 13F filings for Q3 2023.